Study Finds Nurse Educators Significantly Increase Awareness For Product Launch

Quintiles have announced findings from a recent study from a program in which a team of 19 nurse educators helped raise awareness of a newly approved oncology drug for a major pharmaceutical company from 37% to 57%. The results are from an awareness study of 150 clinical practice registered nurses who were provided a survey [...]

Initiation of Clinical Development Builds Upon Broad Potential Shown in Preclinical Studies

Infinity Pharmaceuticals, Inc. (NasdaqGM:INFI – News), an innovative cancer drug discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its oral Hedgehog signaling pathway inhibitor, IPI-926, in patients with advanced and/or metastatic solid tumors.
IPI-926 is a novel, proprietary inhibitor of the Hedgehog signaling pathway. It is a derivative [...]

Paratek Pharmaceuticals, Inc. announced an annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Paratek Pharmaceuticals, Inc. today announced the Company’s lead product, amadacycline, formerly PTK 0796, a first-in-class aminomethylcycline, will be the subject of a Late Breaker poster presentation at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). ICAAC will be held in Washington, D.C. from October 25 – October 28, 2008.
More information on the poster [...]

Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine

Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC(TM) that had been obtained as part of the recently entered partnership with the National Cancer Institute (NCI) in the US.
The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after [...]